

Guideline #	Guideline Name	Type of Change	Brief Description of Guideline Change	Reason for Changes
NEW	Mimrylo (rusfertide)	Positive	On August 28, 2026, the Food and Drug Administration approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. The excess cells can thicken the blood and increase the risk of cardiovascular issues, such as blood clots, stroke and heart attack.	New FDA Drug/Indication
NEW	Etcamah (camizestrant)	Positive	On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (<i>ESR1</i>) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.	New FDA Drug/Indication
ECG 3101	Hicon (sodium iodide I131)	No clinical change	Updated references	Annual Review
ECG 3188	Wayrilz (rilzabrutinib)	No clinical change	Updated references	Annual Review
ECG 3190	Alimta_Pemfexy_Axtle_Pemrydi (pemetrexed)	No clinical change	Updated references	Annual Review
ECG 3192	Cyramza (ramucirumab)	No clinical change	Updated references	Annual Review
ECG 3193	Lynparza (olaparib)	Positive	1) Added additional brand names to abiraterone under indication section 2) Updated references	Annual Review
ECG 3195	Lenvima (lenvatinib)	Positive	1) Updated renal cell carcinoma indication to include use with belzutifan for advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor (FDA label expansion on 9/24/26) 2) Updated references	Annual Review
ECG 3196	Zejula (niraparib)	Positive	1) Updated prostate cancer indication to include use with abiraterone and prednisone in BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC) 2) Updated references	Annual Review
ECG 3197	Kisqali (ribociclib)	Positive	1) Updated indication to include use with Etcamah (camizestrant) for adult members with ER/PR positive, HER2-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy (New FDA drug and label expansion on 9/4/26) 2) Updated references	Annual Review
ECG 3201	Hepzato (melphalan)	No clinical change	Updated references	Annual Review
ECG 3202	Lymphir (denileukin diftitox-cxdl)	No clinical change	Updated references	Annual Review
ECG 3107	Zihera (zanidatamab-hrii)	Positive	On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Zihera, Jazz Pharmaceuticals): 1) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and 2) in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test. 1) Added gastric, esophageal and esophagogastric junction cancers to indication section 2) Updated contraindications/warnings section 3) Updated exclusion criteria 4) Updated references	New FDA Drug/Indication
ECG 3049	Tevimbra (tislelizumab-jsgr)	Positive	On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Zihera, Jazz Pharmaceuticals): 1) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and 2) in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test. 1) Updated gastric, esophageal and esophagogastric junction cancer indications 2) Updated references	New FDA Drug/Indication
ECG 3169	Krazati (adagrasib)	Negative	On September 1, 2026, the FDA finalized the voluntary withdrawal of the indication for Bristol Myers Squibb's (BMS') Krazati (adagrasib), in combination with cetuximab, for adults with KRAS G12C-mutated advanced or metastatic colorectal cancer (CRC) who previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Krazati initially received accelerated approval for this indication on June 21, 2024. The withdrawal follows BMS' disclosure in May 2026 that the Phase 3 KRYSTAL-10 confirmatory trial evaluating Krazati plus cetuximab versus chemotherapy as second-line treatment for patients with CRC and KRAS G12C mutations failed to meet its dual primary endpoints of overall survival and progression-free survival. Importantly, this withdrawal is specific to Krazati's CRC indication and does not affect its FDA-approved indication for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. Amgen's Lumakras (sotorasib) also remains FDA-approved in combination with its own Vectibix (panitumumab) for previously treated KRAS G12C-mutated metastatic CRC. 1) Added FDA withdrawal verbiage to colorectal cancer indication 2) Updated references	FDA Withdrawal
ECG 3204	Erbix (cetuximab)	Negative and Positive	On September 1, 2026, the FDA finalized the voluntary withdrawal of the indication for Bristol Myers Squibb's (BMS') Krazati (adagrasib), in combination with cetuximab, for adults with KRAS G12C-mutated advanced or metastatic colorectal cancer (CRC) who previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Krazati initially received accelerated approval for this indication on June 21, 2024. The withdrawal follows BMS' disclosure in May 2026 that the Phase 3 KRYSTAL-10 confirmatory trial evaluating Krazati plus cetuximab versus chemotherapy as second-line treatment for patients with CRC and KRAS G12C mutations failed to meet its dual primary endpoints of overall survival and progression-free survival. Importantly, this withdrawal is specific to Krazati's CRC indication and does not affect its FDA-approved indication for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. Amgen's Lumakras (sotorasib) also remains FDA-approved in combination with its own Vectibix (panitumumab) for previously treated KRAS G12C-mutated metastatic CRC. 1) Added FDA withdrawal verbiage to colorectal cancer indication 2) Updated colorectal cancer indication to include use with encorafenib + FOLFIRI as initial therapy for metastatic, BRAF V600E mutation positive, KRAS/NRAS wild-type disease 3) Updated references	FDA Withdrawal and Other
ECG 3216	Verzenio (abemaciclib)	Positive and Negative	On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test 1) Added new indication 2) Designated imlunestrant + abemaciclib as an LVR for endocrine sensitive subsequent line as study demonstrated limited incremental clinical value compared with available rechallenge strategies while introducing additional financial toxicity 3) Updated references	New FDA Drug/Indication

ECG 3114	Ibrance (palbociclib)	Positive	On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test 1) Added new indication 2) Updated references	New FDA Drug/Indication
ECG 3233	Hymuo (sevabertinib)	Positive	On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hymuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test 1) Updated indication section 2) Updated references	New FDA Drug/Indication
ECG 3203	Inluriyo (imlunestrant)	Negative	On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. 1) Designated imlunestrant + abemaciclib as an LVR for endocrine sensitive subsequent line as study demonstrated limited incremental clinical value compared with available rechallenge strategies while introducing additional financial toxicity 2) Updated exclusion criteria 3) Updated references	New FDA Drug/Indication
ECG 3018	Opdivo and Opdivo Qvantig (nivolumab IV/SC)	Positive	1) Added Biliary Tract Cancer indication with the regimen of subsequent therapy with ipilimumab for unresectable/metastatic/recurrent biliary tract cancer if the member has not been previously treated with a checkpoint inhibitor and the disease is tumor mutational burden-high (TMB-H)(per NCCN) 2) Updated HCC indication to state "subsequent therapy with ipilimumab for unresectable/metastatic/recurrent HCC if the member has not been previously treated with anti-CTLA4-based combinations" (per NCCN) 3) Updated references	Other
ECG 3155	Yervoy (ipilimumab)	Positive	1) Added Biliary Tract Cancer indication with the regimen of subsequent therapy with nivolumab for unresectable/metastatic/recurrent biliary tract cancer if the member has not been previously treated with a checkpoint inhibitor and the disease is tumor mutational burden-high (TMB-H)(per NCCN) 2) Removed nivolumab + ipilimumab as a low-value regimen in subsequent line setting of metastatic HCC 3) Updated HCC indication to state "subsequent therapy with nivolumab for unresectable/metastatic/recurrent HCC if the member has not been previously treated with anti-CTLA4-based combinations (per NCCN) 4) Updated references	Other
ECG 3035	Enhertu (fam-trastuzumab deruxtecan-nxki)	Positive	Updated verbiage under HER-2 low and HER-2 ultralow metastatic breast cancer indication	Other
ECG 3159	Keytruda and Keytruda Qlex (pembrolizumab IV/SC)	Negative	Changed to an LVR the indication for renal cell carcinoma (clear-cell component) with use in combination with Welireg (belzutifan) in the adjuvant setting as DFS improvement did not yet justify the added cost and toxicity in the absence of demonstrated OS benefit	Other
ECG 3052	Welireg (belzutifan)	Negative and Positive	1) Changed to an LVR the indication for renal cell carcinoma (clear-cell component) with use in combination with Keytruda (pembrolizumab) in the adjuvant setting as DFS improvement did not yet justify the added cost and toxicity in the absence of demonstrated OS benefit 2) Updated renal cell carcinoma indication to include use with lenvatinib for advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor (FDA label expansion on 9/24/26) 3) Updated references	Other
ECG 3205	Braftovi (encorafenib)	Positive	1) Updated colorectal cancer indication to include use with either cetuximab or panitumumab + FOLFIRI as initial therapy for metastatic, BRAF V600E mutation positive, KRAS/NRAS wild-type disease 2) Updated references	Other
ECG 3023	Vectibix (panitumumab)	Positive	1) Updated colorectal cancer indication to include use with encorafenib + FOLFIRI as initial therapy for metastatic, BRAF V600E mutation positive, KRAS/NRAS wild-type disease 2) Updated references	Other
ECG 3026	Evdli/Yondelis	Positive	1) Updated HCPC code for Yondelis 2) Added HCPC code for Evdli	Other
ECG 3039	Generic Drugs	Positive	1) Added "Ivra (melphalan)" and "Infugem (gemcitabine)" to the drug list in Attachment A 2) Removed "Alkeran (melphalan)", "Gemzar (gemcitabine)", "Sylatron (peginterferon alfa-2b)", and "PegIntron (peginterferon alfa-2b)" from drug list in Attachment A	Other
ECG 3074	Bone Modifying Agents	Positive	Updated HCPC codes for denosumab-mobz, denosumab-desu, denosumab-qbde, and denosumab-adet	Other
ECG 3106	Myeloid Growth Factors (MGFs)	Positive	1) Added additional MGF product "Filkri (filgrastim-laha)" to all relevant sections 2) Updated HCPC codes 3) Updated references	Other
ECG 3111	Tasigna (nilotinib)	Positive	1) Added branded product "Danziten" to all relevant sections 2) Updated exclusion criteria 3) Updated references	Other
ECG 3165	Treanda/Bendeka/Belrapzo/Vivimusta (bendamustine)	Positive	Under Coding and Standards section: - Updated long description for J9033 - Added J9066 as a new product	Other
ECG 3223	Retevmo (selpercatinib)	Positive	1) Updated NSCLC indication to include use in the adjuvant setting for RET-fusion positive disease as per LIBRETTO-432 study 2) Updated references	Other
ECG 3270	Decnupaz (pivekimab sunirine-pvzy)	Positive	Updated HCPC code	Other

Change Type	Definition
Positive Change	Expands access, adds new covered indications, broadens eligibility, removes restrictions, adds new drugs/products, or otherwise makes approval criteria more permissive. Examples include FDA label expansions, adding a new indication, adding a new product/biosimilar, or easing clinical criteria.
Negative Change	Restricts access, narrows eligibility, adds new requirements, removes previously covered indications, tightens approval criteria, or otherwise makes approval more restrictive. This may include new step therapy requirements, additional documentation requirements, more stringent clinical criteria, or removal of coverage pathways.
No Clinical Change	No impact to coverage criteria or member/provider access. Changes are administrative only, such as HCPCS updates, reference updates, formatting changes, contraindication wording updates, or annual review maintenance.